Biocryst Pharmaceuticals
Open
$9.36
Prev. Close
$9.36
High
$9.36
Low
$9.35
Market Snapshot
$1.89B
7.2
-0.43
$450.71M
435
BioCryst Pharmaceuticals, Inc. is a biotechnology company. The company is headquartered in Durham, North Carolina and currently employs 435 full-time employees. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Its portfolio also includes navenibart, which is a late-stage, long-acting plasma kallikrein inhibitor. The company has also obtained an early-stage program for atopic dermatitis, STAR0310.
emptyResult
BioCryst Pharmaceuticals, Inc. is a biotechnology company. The company is headquartered in Durham, North Carolina and currently employs 435 full-time employees. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Its portfolio also includes navenibart, which is a late-stage, long-acting plasma kallikrein inhibitor. The company has also obtained an early-stage program for atopic dermatitis, STAR0310.
Recently from Cashu
BioCryst Pharmaceuticals' Q4 Earnings Show Commitment to Rare Disease Treatment Innovations
BioCryst Pharmaceuticals: Advancements in Rare Disease Treatments Highlighted in Q4 Earnings Report BioCryst Pharmaceuticals (NASDAQ:BCRX) presents a compelling narrative in its fourth-quarter earning…
BioCryst Pharmaceuticals Reports Strong Earnings and Promising Future in Rare Disease Treatments
BioCryst Pharmaceuticals: A Strong Finish to the Fiscal Year and a Promising Future BioCryst Pharmaceuticals (NASDAQ:BCRX) announces its fourth-quarter earnings, reflecting solid progress in the bioph…
BioCryst Pharmaceuticals Receives FDA Approval for Pediatric Orladeyo Treatment in HAE
BioCryst Pharmaceuticals Gains FDA Approval for Pediatric HAE Treatment In a landmark decision, the U.S. Food and Drug Administration (FDA) has approved BioCryst Pharmaceuticals Inc.'s oral pellet for…
Biocryst Pharmaceuticals (BCRX) Receives FDA Approval for Pediatric HAE Treatment, Orladeyo
BioCryst Pharmaceuticals Secures FDA Approval for Pediatric HAE Treatment BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) achieves a significant milestone as the U.S. Food and Drug Administration (FDA) gr…